Autoantibody detection with indirect immunofluorescence on HEp-2 cells: Starting serum dilutions for systemic rheumatic diseases

Highlights ► This paper evaluates the clinical and economic impact generated by starting ANA dilution at 1:160. ► A total of 13,233 samples were processed, and only ANA dilutions of 1:160 and higher showed significantly increased positive predictive value for anti-ENA and anti-dsDNA when compared to...

Full description

Saved in:
Bibliographic Details
Published in:Immunology letters 2011-10, Vol.140 (1), p.30-35
Main Authors: González, Delia Almeida, León, Antonio Cabrera de, Varela, Alfredo Roces, García, Miriam García, Rahola, Marta de Sequera, Pérez, María del Cristo Rodríguez, Hernández, Ana González, Falcón, María José Falcón, Díaz, Buenaventura Brito
Format: Article
Language:English
Subjects:
Allergy and Immunology
Anti-DNA antibodies
Anti-ENA antibodies
Antibodies, Antinuclear - blood
Antinuclear antibodies
Autoantibodies
Cell Line, Tumor
Costs
Costs and Cost Analysis
Economics
Fluorescent Antibody Technique, Indirect
Humans
Immunofluorescence
Indirect immunofluorescence technique
Predictive Value of Tests
Radioimmunoassay
Reference Values
Rheumatic diseases
Rheumatic Diseases - blood
Rheumatic Diseases - economics
Rheumatic Diseases - immunology
Serologic Tests - economics
Serologic Tests - methods
Titrimetry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► This paper evaluates the clinical and economic impact generated by starting ANA dilution at 1:160. ► A total of 13,233 samples were processed, and only ANA dilutions of 1:160 and higher showed significantly increased positive predictive value for anti-ENA and anti-dsDNA when compared to 1:40 titer. ► The cut-off 1:160 achieved making 17% less ANA tests, 42% less anti-ENA determinations and 36% less anti-dsDNA tests. ► Setting the starting dilution of ANA at 1:160 avoids unnecessary studies, increases ANA positive predictive values for anti-ENA and anti-dsDNA, and generates clinical and economic benefits.
ISSN:0165-2478
1879-0542
DOI:10.1016/j.imlet.2011.06.001